Skip to content

Centogene and Evotec expand collaboration into Gaucher disease

August 20, 2020

Centogene (NASDAQ:CNTG) and Evotec (OTCPK:EVOTF) have expanded their existing drug discovery partnership related to Gaucher disease – a genetic lysosomal storage disorder caused by mutations in the glucocerebrosidase gene. The parties intend to develop a treatment for Gaucher patients.

The partnership brings together Evotec’s induced pluripotent stem cell (“iPSC”) platform and drug discovery capabilities with Centogene’s global proprietary rare disease platform.

The collaboration builds on the partnership Evotec and Centogene entered in 2018 with the goal to discover and develop novel small molecules in rare hereditary metabolic diseases.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: